Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.9
5.4
Journals
Biosensors
Special Issues
COVID-19 Biosensing Technology
share announcement

COVID-19 Biosensing Technology

A special issue of Biosensors (ISSN 2079-6374). This special issue belongs to the section "Biosensors and Healthcare".

Deadline for manuscript submissions: closed (30 December 2023) | Viewed by 7642

Special Issue Editor

Prof. Dr. Miguel Holgado

E-Mail Website
Guest Editor
Group leader of the Optics, Photonics and Biophotonics group in the Center for Biomedical Technology (CTB), Universidad Politécnica de Madrid, 28223 Madrid, Spain
Interests: point of care systems based on optical detection; optoelectronics and biophotonics; optical readout systems; simulation and design of photonic structures as optical transducers
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Faced with the pandemic caused by SARS-COV-2, a large number of significant technologies have been developed to solve this health crisis. Biosensing technologies are paying a key role; for this reason, we believe that it is now the time to introduce a Special Issue on COVID-19 Biosensing Technology. I am pleased to invite you to submit a contribution for this Special Issue of Biosensors that will focus on the following topics related to biosensensing technology, but not limited, applied to COVID19. If you have a relevant research to this area, in concrete relating to technologies:

  • COVID-19 biosensing technologies;
  • Biosenros for measuring SARS-COV-2;
  • Immunosensors for COVID19;
  • Multiplexed COVID19 for measuring biomarkers;
  • Biosensors for measuring COVID19 severity;
  • Optical biosensors;
  • SPR based biosensors;
  • Photonic biosensors;
  • Electrochemical biosensors;
  • Nanoparticles based biosensors;
  • Highly multiplexed biosensors;
  • COVID-19 in vitro detection systems;
  • Lateral flow devices for SARS-COV-2 detection;
  • ELISA technologies for COVID19 screening;
  • Microarray technologies for COVID19 screening;
  • Progress and development biosensing technolies for COVID-19;
  • Biosensors technology for SARS-COV-2 detection in saliva;
  • Biosensors technology for COVID19 biomarkers in saliva;
  • Biosensors technology for COVID19 biomarkers in serum;
  • Biosensing technologies for SARS-COV-2 detection in waste water;
  • Alternative COVID19 biosensing technologies;
  • Other COVID19 biosensing technologies.

Prof. Dr. Miguel Holgado
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biosensors is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 3973 KiB  
Article
Proof-of-Concept: Smartphone- and Cloud-Based Artificial Intelligence Quantitative Analysis System (SCAISY) for SARS-CoV-2-Specific IgG Antibody Lateral Flow Assays
by Samir Kumar, Taewoo Ko, Yeonghun Chae, Yuyeon Jang, Inha Lee, Ahyeon Lee, Sanghoon Shin, Myung-Hyun Nam, Byung Soo Kim, Hyun Sik Jun and Sungkyu Seo
Biosensors 2023, 13(6), 623; https://doi.org/10.3390/bios13060623 - 5 Jun 2023
Cited by 4 | Viewed by 1860
Abstract
Smartphone-based point-of-care testing (POCT) is rapidly emerging as an alternative to traditional screening and laboratory testing, particularly in resource-limited settings. In this proof-of-concept study, we present a smartphone- and cloud-based artificial intelligence quantitative analysis system (SCAISY) for relative quantification of SARS-CoV-2-specific IgG antibody [...] Read more.
Smartphone-based point-of-care testing (POCT) is rapidly emerging as an alternative to traditional screening and laboratory testing, particularly in resource-limited settings. In this proof-of-concept study, we present a smartphone- and cloud-based artificial intelligence quantitative analysis system (SCAISY) for relative quantification of SARS-CoV-2-specific IgG antibody lateral flow assays that enables rapid evaluation (<60 s) of test strips. By capturing an image with a smartphone camera, SCAISY quantitatively analyzes antibody levels and provides results to the user. We analyzed changes in antibody levels over time in more than 248 individuals, including vaccine type, number of doses, and infection status, with a standard deviation of less than 10%. We also tracked antibody levels in six participants before and after SARS-CoV-2 infection. Finally, we examined the effects of lighting conditions, camera angle, and smartphone type to ensure consistency and reproducibility. We found that images acquired between 45° and 90° provided accurate results with a small standard deviation and that all illumination conditions provided essentially identical results within the standard deviation. A statistically significant correlation was observed (Spearman correlation coefficient: 0.59, p = 0.008; Pearson correlation coefficient: 0.56, p = 0.012) between the OD450 values of the enzyme-linked immunosorbent assay and the antibody levels obtained by SCAISY. This study suggests that SCAISY is a simple and powerful tool for real-time public health surveillance, enabling the acceleration of quantifying SARS-CoV-2-specific antibodies generated by either vaccination or infection and tracking of personal immunity levels. Full article
(This article belongs to the Special Issue COVID-19 Biosensing Technology)
►▼ Show Figures

Figure 1

14 pages, 4697 KiB  
Article
Integration of Multiple Interferometers in Highly Multiplexed Diagnostic KITs to Evaluate Several Biomarkers of COVID-19 in Serum
by Ana María M. Murillo, Luis G. Valle, Yolanda Ramírez, María Jesús Sánchez, Beatriz Santamaría, E. Molina-Roldan, Isabel Ortega-Madueño, Elena Urcelay, Luca Tramarin, Pedro Herreros, Araceli Díaz-Perales, María Garrido-Arandia, Jaime Tome-Amat, Guadalupe Hernández-Ramírez, Rocío L. Espinosa, María F. Laguna and Miguel Holgado
Biosensors 2022, 12(9), 671; https://doi.org/10.3390/bios12090671 - 23 Aug 2022
Cited by 2 | Viewed by 1640
Abstract
In the present work, highly multiplexed diagnostic KITs based on an Interferometric Optical Detection Method (IODM) were developed to evaluate six Coronavirus Disease 2019 (COVID-19)-related biomarkers. These biomarkers of COVID-19 were evaluated in 74 serum samples from severe, moderate, and mild patients with [...] Read more.
In the present work, highly multiplexed diagnostic KITs based on an Interferometric Optical Detection Method (IODM) were developed to evaluate six Coronavirus Disease 2019 (COVID-19)-related biomarkers. These biomarkers of COVID-19 were evaluated in 74 serum samples from severe, moderate, and mild patients with positive polymerase chain reaction (PCR), collected at the end of March 2020 in the Hospital Clínico San Carlos, in Madrid (Spain). The developed multiplexed diagnostic KITs were biofunctionalized to simultaneously measure different types of specific biomarkers involved in COVID-19. Thus, the serum samples were investigated by measuring the total specific Immunoglobulins (sIgT), specific Immunoglobulins G (sIgG), specific Immunoglobulins M (sIgM), specific Immunoglobulins A (sIgA), all of them against SARS-CoV-2, together with two biomarkers involved in inflammatory disorders, Ferritin (FER) and C Reactive Protein (CRP). To assess the results, a Multiple Linear Regression Model (MLRM) was carried out to study the influence of IgGs, IgMs, IgAs, FER, and CRP against the total sIgTs in these serum samples with a goodness of fit of 73.01% (Adjusted R-Squared). Full article
(This article belongs to the Special Issue COVID-19 Biosensing Technology)
►▼ Show Figures

Figure 1

Review

Jump to: Research

17 pages, 3630 KiB  
Review
Unraveling the Dynamics of SARS-CoV-2 Mutations: Insights from Surface Plasmon Resonance Biosensor Kinetics
by Devi Taufiq Nurrohman and Nan-Fu Chiu
Biosensors 2024, 14(2), 99; https://doi.org/10.3390/bios14020099 - 13 Feb 2024
Viewed by 1327
Abstract
Surface Plasmon Resonance (SPR) technology is known to be a powerful tool for studying biomolecular interactions because it offers real-time and label-free multiparameter analysis with high sensitivity. This article summarizes the results that have been obtained from the use of SPR technology in [...] Read more.
Surface Plasmon Resonance (SPR) technology is known to be a powerful tool for studying biomolecular interactions because it offers real-time and label-free multiparameter analysis with high sensitivity. This article summarizes the results that have been obtained from the use of SPR technology in studying the dynamics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations. This paper will begin by introducing the working principle of SPR and the kinetic parameters of the sensorgram, which include the association rate constant (ka), dissociation rate constant (kd), equilibrium association constant (KA), and equilibrium dissociation constant (KD). At the end of the paper, we will summarize the kinetic data on the interaction between angiotensin-converting enzyme 2 (ACE2) and SARS-CoV-2 obtained from the results of SPR signal analysis. ACE2 is a material that mediates virus entry. Therefore, understanding the kinetic changes between ACE2 and SARS-CoV-2 caused by the mutation will provide beneficial information for drug discovery, vaccine development, and other therapeutic purposes. Full article
(This article belongs to the Special Issue COVID-19 Biosensing Technology)
►▼ Show Figures

Figure 1

29 pages, 5082 KiB  
Review
Recent Advances in Quantum Dot-Based Lateral Flow Immunoassays for the Rapid, Point-of-Care Diagnosis of COVID-19
by Seyyed Mojtaba Mousavi, Masoomeh Yari Kalashgrani, Ahmad Gholami, Navid Omidifar, Mojtaba Binazadeh and Wei-Hung Chiang
Biosensors 2023, 13(8), 786; https://doi.org/10.3390/bios13080786 - 3 Aug 2023
Cited by 2 | Viewed by 2103
Abstract
The COVID-19 pandemic has spurred demand for efficient and rapid diagnostic tools that can be deployed at point of care to quickly identify infected individuals. Existing detection methods are time consuming and they lack sensitivity. Point-of-care testing (POCT) has emerged as a promising [...] Read more.
The COVID-19 pandemic has spurred demand for efficient and rapid diagnostic tools that can be deployed at point of care to quickly identify infected individuals. Existing detection methods are time consuming and they lack sensitivity. Point-of-care testing (POCT) has emerged as a promising alternative due to its user-friendliness, rapidity, and high specificity and sensitivity. Such tests can be conveniently conducted at the patient’s bedside. Immunodiagnostic methods that offer the rapid identification of positive cases are urgently required. Quantum dots (QDs), known for their multimodal properties, have shown potential in terms of combating or inhibiting the COVID-19 virus. When coupled with specific antibodies, QDs enable the highly sensitive detection of viral antigens in patient samples. Conventional lateral flow immunoassays (LFAs) have been widely used for diagnostic testing due to their simplicity, low cost, and portability. However, they often lack the sensitivity required to accurately detect low viral loads. Quantum dot (QD)-based lateral flow immunoassays have emerged as a promising alternative, offering significant advancements in sensitivity and specificity. Moreover, the lateral flow immunoassay (LFIA) method, which fulfils POCT standards, has gained popularity in diagnosing COVID-19. This review focuses on recent advancements in QD-based LFIA for rapid POCT COVID-19 diagnosis. Strategies to enhance sensitivity using QDs are explored, and the underlying principles of LFIA are elucidated. The benefits of using the QD-based LFIA as a POCT method are highlighted, and its published performance in COVID-19 diagnostics is examined. Overall, the integration of quantum dots with LFIA holds immense promise in terms of revolutionizing COVID-19 detection, treatment, and prevention, offering a convenient and effective approach to combat the pandemic. Full article
(This article belongs to the Special Issue COVID-19 Biosensing Technology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop